Summary
This study investigates the role of platelet-activating factor (PAF) in experimental pancreatitis. The concentration of PAF quantified in ascites of bile-induced pancreatitis by radioimmunoassay (RIA) ranged from 3.67 ± 0.39 pmol/mL 2 h to 0.954 ± 0.39 pmol/mL 10 h after injection of taurocholate. Administration of a potent PAF antagonist, WEB-2170, prior to injection of taurocholate prolonged mean survival time in rats receiving iv camostate and albumin (46.4 h,n = 15, vs controls 38.3 h,n = 13). However, the survival rate after 72 h was not improved. The histologically estimated severity of pancreatitis and pancreatic enzymes in blood, tissue, or ascites was not affected. WEB-2170 had no effect on survival when injected simultaneously with taurocholate into the pancreatic duct or given iv after induction of pancreatitis (1, 0.1, or 0.01 mg/kg WEB-2170 vs controls). Subcutaneous injection of 10 mg/kg WEB-2170 also did not improve survival in pancreatitis induced by choline-deficient, ethionine-supplemented diet in mice. It is concluded that administration of a PAF antagonist after the onset of severe experimental pancreatitis does not influence its outcome, although activation of PAF may play a role in the pathogenesis of pancreatitis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Soling HD, Fest W. Synthesis of l-O-Alkyl-2-acetyl-sn- glycero-3-phosphocholine (platelet-activating factor) in exocrine glands and its control by secretagogues.J Biol Chem 1986; 261: 13,916–13,922.
Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspectives in platelet activating factor research.Pharmacol Rev 1987; 39: 97–145.
Soling HD, Eibl H, Fest W. Acetylcholine-like effects of l-O-Alkyl-2-acetyl-su-glycero-3-phosphocholine (‘platelet-activating factor’) and its analogues in exocrine secretory glands.Eur J Bio chem 1984; 144: 65–72.
Leonhardt U, Seidensticker F, Fussek M, Stockmann F, Creutzfeldt W. Influence of the CCK-antagonist loxi- glumide on bile-induced experimental pancreatitis.Int J Pancreatol 1991; 10: 73–79.
Wereszczynska-Siemiatkowska U, Nebendahl K, Pohl U, Otto J, Gröne HJ, Wilrns H, Lankisch PG. Influence of buprenorphine on acute experimental pancreatitis.Res Exp Med 1987; 187: 211–216.
Casals-Stenzel J, Heuer HO. Use of WEB 2086 and WEB 2170 as platelet activating factor antagonists.Methods Enzymol 1990; 187: 455–465.
Niederau C, Crass RA, Silver G, Ferrell LD, Grendell JH. Therapeutic regimens in acute experimental hemorrhagic pancreatitis: effects of hydration, oxygenation, peritoneal lavage, and a potent protease inhibitor.Gastroenterology 1988; 95: 1648–1657.
Leonhardt U, Seidensticker F, Fussek M, Stockmann F, Creutzfeldt W. Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis.Gut 1990; 31: 934–937.
Lankisch PG, Pohl U, Göke B, Otto J, Wereszczynska-Siemiatkowska U, Gröne HJ, Ralph G. Effect of FOY-305 (camostate) on severe acute pancreatitis in two experimental animal models.Gastroenterology 1989; 96: 193–199.
Leonhardt U, Seidensticker F, Stöckmann F, Creutzfeldt W. Effect of camostate administration for 2 weeks on experimental pancreatitis.Pancreas (in press).
Leonelli FM, Leong LL, Sturm MJ, Strophair JA, Clarke GM, Taylor RR. Plasma levels of the lyso-derivative of platelet activating factor in acute severe systemic illness.Clin Sci 1989: 77: 561–566.
Sirois MG, Jancar 5, Braquet P, Plante GE, Sirois P. PAF increases vascular permeability in selected tissues: effect of BN-52021 and L-655,240.Prostaglandins 1988; 36: 631–644.
Jancar S, De Giaccobi G, Mariano M, Mencia-Huerta JM, Sirois P, Braquet P. Immune-complex induced pancreatitis: effect of BN 52021, a selective antagonist of platelet activating factor.Prostaglandins 1988; 35: 757–770.
Emanuelli G, Montrucchio G, Gaia E, Dughera L, Corvetti G, Gubetta L. Experimental acute pancreatitis induced by platelet activating factor in rabbits.Am J Pathol 1989; 134:315–326.
Casals-Stenzel J, Muacevic G, Weber KH. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.J Pharmacol Exp Ther 1987; 241:974–981.
Dewald B, Baggiolini M. Evaluation of platelet activat- ing factor antagonists using human neutrophils in a microtiter plate assay.Biochem Pharmacol 1987; 36(15): 2505–2510.
Handley DA, van Valen RG, Melden MK, Houlihan WJ, Saunders RN. Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412.J Pharmacol Exp Ther 1988; 247: 617–623.
Dabrowski A, Gabryelewicz A, Chyczewsky L. The effect of platelet activating factor antagonist (BN 52021) on ceru- lein-induced acute pancreatitis with reference to oxygen radicals.Int J Pancreatol 1991; 8: 1–11.
Creutzfeldt W. Pathogenesis of pancreatitis: the rational for its treatment by inhibitors of enzyme activity and secre- tion.Biomed Res 1989; 10(Suppl. 1): 15–24.
Lankisch PG, Pohl U, Otto J, Rahlf G. When should treatment of acute pancreatitis be started?: the early phase of bile-induced pancreatitis.Res Exp Med 1988; 188: 123–129.
Lombardi B, Estes LW, Longecker DS. Acute hemorrhagic pancreatitis (massive necrosis) induced in mice by DL-ethionine fed with a choline-deficient diet.Am J Pathol 1975; 79: 465–476.
Rao KN, Tuma J, Lombardi B. Acute hemorrhagic pancreatic necrosis in mice.Gastroenterology 1976; 70: 720–726.
Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH. Pharmacologic activity of bepafant (WEB-2170), a new and selective hetrazepinoic antagonist of platelet activating factor.J Pharmacol Exp Ther 1990; 255: 962–968.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leonhardt, U., Fayyazzi, A., Seidensticker, F. et al. Influence of a platelet-activating factor antagonist on severe pancreatitis in two experimental models. Int J Pancreatol 12, 161–166 (1992). https://doi.org/10.1007/BF02924640
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02924640